{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:27:50Z","timestamp":1790490470370,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Piramal Imaging","award":["ZVK20150323"],"award-info":[{"award-number":["ZVK20150323"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.nucmedbio.2019.01.009","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T18:23:27Z","timestamp":1548786207000},"page":"32-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Accuracy of [68Ga]Ga-RM2-PET\/CT for diagnosis of primary prostate cancer compared to histopathology"],"prefix":"10.1016","volume":"70","author":[{"given":"Thomas F.","family":"Fassbender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Maecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Drendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula A.","family":"Jilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0005","first-page":"990","article-title":"PET imaging of prostate cancer using carbon-11-choline","volume":"39","author":"Hara","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0010","first-page":"1249","article-title":"Imaging prostate cancer with 11 C-choline PET\/CT","volume":"47","author":"Reske","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0015","first-page":"110","article-title":"Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer","volume":"61","author":"Degrado","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0020","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","article-title":"Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer","volume":"7","author":"Eder","year":"2014","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0025","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.7150\/thno.15344","article-title":"Ga-68 HBED-CC-PSMA PET\/CT versus histopathology in primary localized prostate cancer: a voxel-wise comparison","volume":"6","author":"Zamboglou","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.bcp.2004.11.003","article-title":"Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP)","volume":"69","author":"Nakagawa","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0035","first-page":"1139","article-title":"Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[D-Tyr6,b-ALA11,PHE13,NLE14]Bombesin(6-14)","volume":"8","author":"Reubi","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0040","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.7150\/thno.14958","article-title":"Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist (68)Ga-RM2 and PET","volume":"6","author":"Stoykow","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0045","first-page":"1152","article-title":"Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation","volume":"59","author":"Markwalder","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/pros.22743","article-title":"Early over-expression of GRP receptors in prostatic carcinogenesis","volume":"74","author":"K\u00f6rner","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0055","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s002590000355","article-title":"Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study","volume":"27","author":"Van de Wiele","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0060","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2967\/jnumed.114.147116","article-title":"Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer","volume":"56","author":"Sah","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0065","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-12-3490","article-title":"In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548","volume":"19","author":"K\u00e4hk\u00f6nen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.116.178889","article-title":"Theranostic perspectives in prostate Cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results","volume":"58","author":"Nock","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0075","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1158\/1078-0432.CCR-08-3145","article-title":"Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides","volume":"15","author":"Mansi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0080","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1158\/1078-0432.CCR-16-2745","article-title":"Bombesin antagonist-based radiotherapy of prostate cancer combined with WST-11 vascular targeted photodynamic therapy","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0085","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2967\/jnumed.112.112169","article-title":"Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin","volume":"54","author":"Dumont","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-010-1596-9","article-title":"Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours","volume":"38","author":"Mansi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0095","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00259-017-3702-8","article-title":"Diagnosis of recurrent prostate cancer with PET\/CT imaging using the gastrin-releasing peptide receptor antagonist Ga-68 RM2: preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET\/CT","volume":"44","author":"Wieser","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2967\/jnumed.115.168393","article-title":"Pilot comparison of Ga-68 RM2 PET and Ga-68 PSMA-11 PET in patients with biochemically recurrent prostate cancer","volume":"57","author":"Minamimoto","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0105","first-page":"1","article-title":"Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms","author":"Wirth","year":"2009","journal-title":"Therapie"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0110","series-title":"TNM classification of malignant Tumours","author":"Wittekind","year":"2009"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0115","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0120","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma","volume":"1","author":"Epstein","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0125","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0130","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.nucmedbio.2019.01.009_bb0135","series-title":"Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Leitlinienreport","author":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft","year":"2016"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805118303561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805118303561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:28:22Z","timestamp":1760848102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805118303561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":27,"alternative-id":["S0969805118303561"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2019.01.009","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accuracy of [68Ga]Ga-RM2-PET\/CT for diagnosis of primary prostate cancer compared to histopathology","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2019.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}